{"id":124168,"date":"2026-09-02T07:20:51","date_gmt":"2026-09-02T07:20:51","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/124168\/"},"modified":"2026-09-02T07:20:51","modified_gmt":"2026-09-02T07:20:51","slug":"chinas-simcere-zaiming-signs-1-5-b-deal-with-roche-for-sim0660-global-development","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/124168\/","title":{"rendered":"China&#8217;s Simcere Zaiming signs $1.5 B deal with Roche for SIM0660 global development"},"content":{"rendered":"<p>\t\t\t\t\t\tChina&#8217;s Simcere Zaiming signs $1.5 B deal with Roche for SIM0660 global development<\/p>\n<p class=\"float-left\">September 2, 2026 | Wednesday | News<\/p>\n<p>\t\t\t\t\t\t\tSIM0660 is a tri-specific antibody developed by Simcere Zaiming using its T-cell engager poly-specific antibody technology<\/p>\n<p>\t\t\t\t\t\t\t\t<img decoding=\"async\" src=\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/09\/screenshot_2_9_2026_1264_www_bing_com-28296.jpeg\" class=\"img-fluid w-100 pl-5 pr-5\" alt=\"image credit- shutterstock\"\/><\/p>\n<p class=\"mt-3 text-center\">image credit- shutterstock<\/p>\n<p style=\"text-align: justify;\">Simcere Zaiming, a subsidiary of China-based Simcere Pharmaceutical Group, has entered into an exclusive global licensing agreement with Roche for the development and commercialisation of SIM0660, a tri-specific antibody targeting CD79a, CD19, and CD3, with therapeutic potential across B-cell-mediated diseases.<\/p>\n<p class=\"prntal\" style=\"text-align: justify;\">Under the terms of the agreement, Roche will acquire exclusive global rights to develop, manufacture, and commercialise SIM0660.<\/p>\n<p class=\"prntal\" style=\"text-align: justify;\">Simcere Zaiming is eligible to receive up to $1.5 billion in total payments, including $75 million in upfront. Simcere Zaiming is also eligible to receive tiered royalties of up to double digits on future net sales.<\/p>\n<p class=\"prntal\" style=\"text-align: justify;\">SIM0660 is a tri-specific antibody developed by Simcere Zaiming using its T-cell engager poly-specific antibody technology. The molecule combines a CD3-engaging arm with binding domains targeting the two B-cell antigens CD79a and CD19 to induce potent T cell-mediated cytotoxicity while limiting cytokine release.<\/p>\n<p class=\"prntal\" style=\"text-align: justify;\">With its potential first-in-class dual-targeting approach to CD79a and CD19, SIM0660 is designed to provide broad coverage across B-cell mediated diseases, and may offer a differentiated therapeutic approach for patients previously treated with CD20- or CD19-directed therapies. In addition, SIM0660 also has therapeutic potential for B-cell-mediated autoimmune diseases, where targeted depletion of pathogenic B cells may provide clinical benefit.<\/p>\n<p class=\"prntal\" style=\"text-align: justify;\">To date, Simcere Pharmaceutical Group has completed six out-licensing transactions, with a potential aggregate total consideration exceeding $6.1 billion.<\/p>\n","protected":false},"excerpt":{"rendered":"China&#8217;s Simcere Zaiming signs $1.5 B deal with Roche for SIM0660 global development September 2, 2026 | Wednesday&hellip;\n","protected":false},"author":2,"featured_media":124169,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[60759,351,2541,134,60546,60758],"class_list":["post-124168","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-billion-dollar","tag-china","tag-ma","tag-roche","tag-simcere-zaiming","tag-trispecific-antibodies"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117200243224068478","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/124168","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=124168"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/124168\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/124169"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=124168"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=124168"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=124168"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}